sacituzumab tirumotecan

all catalysts(0)

nothing on the calendar yet

News(9)

• Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
  Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…
  biospace · 5d ago
• Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
  Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
  biospace · 9d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 2mo ago
• Kelun pads efficacy profile of Merck-partnered ADC; Europe will have to wait for Boehringer's Hernexeos
  Plus, news about Vogenx and Orakl Oncology. 🇨🇳 Kelun touts China data for sac-TMT: Kelun-Biotech announced on Tuesday that its Merck-partnered antibody-drug conjugate sacituzumab tirumotecan succ…
  endpoints · 2mo ago
• Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
  The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…
  biospace · 2mo ago
• Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
  Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
  biopharma_dive · 3mo ago
• At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
  Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
  biopharma_dive · 4mo ago
• Merck ADC, licensed from China, hits mark in first big global trial
  The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
  biopharma_dive · 4mo ago
• Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
  Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
  onclive · 4mo ago